Literature DB >> 2016749

Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins.

U Baumann1, R Huber, W Bode, D Grosse, M Lesjak, C B Laurell.   

Abstract

The crystal structure of proteolytically modified human alpha 1-antichymotrypsin (ACT), a member of the serpin superfamily, has been solved by Paterson search techniques and refined to an R-factor of 18.0% at 2.7 A resolution with mean deviations from standard bond lengths and angles of 0.013 A and 3.1 degrees, respectively. The final model consists of 374 amino acid residues, 126 solvent molecules and five sugar residues. Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated. The structure of cleaved ACT is compared with cleaved alpha 1-antitrypsin (alpha 1 PI) and with plakalbumin, which are prototypical models for cleaved and intact serpins, respectively. Cleaved ACT is very similar to cleaved alpha 1 PI; in particular, it has strand s4A, which is liberated by proteolysis, inserted as the middle strand in beta-sheet A. ACT and alpha 1 PI differ locally only at sites of insertions, except at the segment s3C-turn-s4C, which is displaced by several angström units. This region of ACT is involved in DNA binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016749     DOI: 10.1016/0022-2836(91)90704-a

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  22 in total

1.  Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease.

Authors:  B Gooptu; B Hazes; W S Chang; T R Dafforn; R W Carrell; R J Read; D A Lomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

3.  Crystal structure of viral serpin crmA provides insights into its mechanism of cysteine proteinase inhibition.

Authors:  M Simonovic; K Volz
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

4.  The mechanism of fibril formation of a non-inhibitory serpin ovalbumin revealed by the identification of amyloidogenic core regions.

Authors:  Naoki Tanaka; Yumi Morimoto; Yurika Noguchi; Tomoko Tada; Tomonori Waku; Shigeru Kunugi; Takashi Morii; Yin-Fai Lee; Takashi Konno; Nobuyuki Takahashi
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

5.  Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy.

Authors:  H Koloczek; A Banbula; G S Salvesen; J Potempa
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

6.  Structural mechanism for the carriage and release of thyroxine in the blood.

Authors:  Aiwu Zhou; Zhenquan Wei; Randy J Read; Robin W Carrell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

7.  Probing serpin reactive-loop conformations by proteolytic cleavage.

Authors:  W S Chang; M R Wardell; D A Lomas; R W Carrell
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

8.  Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins.

Authors:  W S Chang; J Whisstock; P C Hopkins; A M Lesk; R W Carrell; M R Wardell
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

9.  A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization.

Authors:  Malgorzata Wilczynska; Sergei Lobov; Per-Ingvar Ohlsson; Tor Ny
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

10.  The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

Authors:  Christian Boudier; Ann Gils; Paul J Declerck; Joseph G Bieth
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.